Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
Can J Ophthalmol
; 50(3): 209-16, 2015 Jun.
Article
en En
| MEDLINE
| ID: mdl-26040221
ABSTRACT
OBJECTIVE:
To compare the efficacy and safety of ranibizumab 0.5 mg intravitreal injection, as monotherapy or in combination with laser, with laser monotherapy in patients with visual impairment caused by diabetic macular edema.DESIGN:
Twelve-month, multicentre, open-label, parallel-group, randomized, active-control study.PARTICIPANTS:
A total of 220 (ranibizumab monotherapy n = 75, ranibizumab + laser n = 73, laser monotherapy n = 72) patients with a diagnosis of type I or II diabetes and visual impairment caused by macular edema were included in the efficacy analysis.METHODS:
Ranibizumab was initiated with a fixed loading phase of 3 monthly injections followed by as needed therapy until stable vision achievement. Efficacy end points were the change in best corrected visual acuity (BCVA), change in central retinal thickness (CRT) measured by optical coherence tomography, proportion achieving a 15-letter BCVA gain, and 12-month Visual Function Questionnaire-25 (VFQ-25) score. Safety was assessed with the incidence and severity of adverse events.RESULTS:
At 12 months, significant (p < 0.001) mean BCVA improvements were observed for both the ranibizumab monotherapy (+8.9 [95% confidence interval (CI) 7.0-10.7] letters) and the ranibizumab + laser (+8.2 [95% CI 6.0-10.4] letters) groups compared with the laser monotherapy group (+0.3 [95% CI -2.9 to 3.5] letters). Similarly, a better response in terms of CRT improvement, BCVA letter gain, and VFQ-25 was observed in both ranibizumab groups compared with laser monotherapy. The safety profile was comparable in the 2 ranibizumab groups.CONCLUSIONS:
Ranibizumab as monotherapy or combined with laser resulted in significantly higher improvements in visual acuity and vision-related quality of life at month 12 as compared with laser monotherapy.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Edema Macular
/
Coagulación con Láser
/
Inhibidores de la Angiogénesis
/
Retinopatía Diabética
/
Ranibizumab
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Can J Ophthalmol
Año:
2015
Tipo del documento:
Article